Cargando…

Prescription Trends for Hepatocellular Carcinoma Drugs are mirrored by Online Searches

BACKGROUND: Hepatocellular Carcinoma (HCC) is a major contributor to cancer-related deaths globally. Advancements in immune and molecular therapies have led to more targeted and safer systemic treatments for advanced and unresectable HCC, replacing the use of non-specific chemotherapies. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Berning, P, Schroer, A E, Dzaye, O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596087/
http://dx.doi.org/10.1093/eurpub/ckad160.818
_version_ 1785125021267525632
author Berning, P
Schroer, A E
Dzaye, O
author_facet Berning, P
Schroer, A E
Dzaye, O
author_sort Berning, P
collection PubMed
description BACKGROUND: Hepatocellular Carcinoma (HCC) is a major contributor to cancer-related deaths globally. Advancements in immune and molecular therapies have led to more targeted and safer systemic treatments for advanced and unresectable HCC, replacing the use of non-specific chemotherapies. This study aims to provide an overview of online search and prescription activity of drugs used for HCC. METHODS: Data from IQVIA National Prescription Audit, a comprehensive audit of nearly all monthly US prescription information, was collected from 2017 to 2022 for FDA-approved HCC drugs. Online searches for these drugs were analyzed for visual and quantitative (Spearman's) correlation. RESULTS: Online searches for HCC drugs in the US increased 1.17-fold between the first quarter(Q1) 2017 and Q4 2022, while prescriptions increased 5.93-fold during this period. Across first line therapies, lenvatinib was most used with a 27.62-fold increase(Q1 2019-Q4 2022), paralleled by a 1.52-fold increase in online searches. Sorafenib use, however, steeply declined by 17.56-fold(Q1 2019-Q4 2022). For second-line and later treatments, cabozantinib was most frequently applied with 3.04-fold increase and 1.62-fold rise in online searches(Q1 2017-Q4 2022). Immunotherapy prescriptions and online searches for pembrolizumab have surged from Q1 2017-Q4 2022, with an increase of 8.03-fold and 1.37-fold, respectively. Lenvatinib (r = 0.90), cabozantinib (r = 0.67), and pembrolizumab (r = 0.54) had the highest correlations between online searches and prescriptions, and all three showed increasing trends. Oncologists(72.40%) were the largest users of the across specialties in 2022, followed by physician assistants/nurse practitioners(16.53%). CONCLUSIONS: Over a 5-year period, the utilization of HCC drugs in the US increased and prescription patterns changed due to positive trial results and guideline changes. There was a positive correlation between online searches and prescription trends for HCC drugs. KEY MESSAGES: • High correlation levels between online searches and prescriptions for HCC drugs with increasing usage. • Online search data can mirror prescriptions trends for HCC drugs.
format Online
Article
Text
id pubmed-10596087
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105960872023-10-25 Prescription Trends for Hepatocellular Carcinoma Drugs are mirrored by Online Searches Berning, P Schroer, A E Dzaye, O Eur J Public Health Poster Walks BACKGROUND: Hepatocellular Carcinoma (HCC) is a major contributor to cancer-related deaths globally. Advancements in immune and molecular therapies have led to more targeted and safer systemic treatments for advanced and unresectable HCC, replacing the use of non-specific chemotherapies. This study aims to provide an overview of online search and prescription activity of drugs used for HCC. METHODS: Data from IQVIA National Prescription Audit, a comprehensive audit of nearly all monthly US prescription information, was collected from 2017 to 2022 for FDA-approved HCC drugs. Online searches for these drugs were analyzed for visual and quantitative (Spearman's) correlation. RESULTS: Online searches for HCC drugs in the US increased 1.17-fold between the first quarter(Q1) 2017 and Q4 2022, while prescriptions increased 5.93-fold during this period. Across first line therapies, lenvatinib was most used with a 27.62-fold increase(Q1 2019-Q4 2022), paralleled by a 1.52-fold increase in online searches. Sorafenib use, however, steeply declined by 17.56-fold(Q1 2019-Q4 2022). For second-line and later treatments, cabozantinib was most frequently applied with 3.04-fold increase and 1.62-fold rise in online searches(Q1 2017-Q4 2022). Immunotherapy prescriptions and online searches for pembrolizumab have surged from Q1 2017-Q4 2022, with an increase of 8.03-fold and 1.37-fold, respectively. Lenvatinib (r = 0.90), cabozantinib (r = 0.67), and pembrolizumab (r = 0.54) had the highest correlations between online searches and prescriptions, and all three showed increasing trends. Oncologists(72.40%) were the largest users of the across specialties in 2022, followed by physician assistants/nurse practitioners(16.53%). CONCLUSIONS: Over a 5-year period, the utilization of HCC drugs in the US increased and prescription patterns changed due to positive trial results and guideline changes. There was a positive correlation between online searches and prescription trends for HCC drugs. KEY MESSAGES: • High correlation levels between online searches and prescriptions for HCC drugs with increasing usage. • Online search data can mirror prescriptions trends for HCC drugs. Oxford University Press 2023-10-24 /pmc/articles/PMC10596087/ http://dx.doi.org/10.1093/eurpub/ckad160.818 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Walks
Berning, P
Schroer, A E
Dzaye, O
Prescription Trends for Hepatocellular Carcinoma Drugs are mirrored by Online Searches
title Prescription Trends for Hepatocellular Carcinoma Drugs are mirrored by Online Searches
title_full Prescription Trends for Hepatocellular Carcinoma Drugs are mirrored by Online Searches
title_fullStr Prescription Trends for Hepatocellular Carcinoma Drugs are mirrored by Online Searches
title_full_unstemmed Prescription Trends for Hepatocellular Carcinoma Drugs are mirrored by Online Searches
title_short Prescription Trends for Hepatocellular Carcinoma Drugs are mirrored by Online Searches
title_sort prescription trends for hepatocellular carcinoma drugs are mirrored by online searches
topic Poster Walks
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596087/
http://dx.doi.org/10.1093/eurpub/ckad160.818
work_keys_str_mv AT berningp prescriptiontrendsforhepatocellularcarcinomadrugsaremirroredbyonlinesearches
AT schroerae prescriptiontrendsforhepatocellularcarcinomadrugsaremirroredbyonlinesearches
AT dzayeo prescriptiontrendsforhepatocellularcarcinomadrugsaremirroredbyonlinesearches